Abstract
Assays for the detection of nucleic acid in serum are likely to be better systems for determining infectivity than indirect ones dependent on detection of virus-encoded proteins such as HBeAg. The hybridization assays are particularly useful in monitoring spontaneous or treatment-related conversion from the "replicative" to "nonreplicative" phase of HBV infection. The simplified technology described in the papers reported in this issue of Hepatology (9, 14) and their future adaptation to nonisotopic systems will rapidly bring these techniques into everyday clinical practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
